European Companies Search Engine
EU funding (€6,306,193): UNDERSTANDING PERFORMANCE CHARACTERISTICS OF LIVE ATTENUATED VACCINES FOR THE PREVENTION AND CONTROL OF AFRICAN SWINE FEVER IN WILD BOAR AND DOMESTIC PIGS Hor1 Jan 2024 EU Research and Innovation programme "Horizon"
Text
UNDERSTANDING PERFORMANCE CHARACTERISTICS OF LIVE ATTENUATED VACCINES FOR THE PREVENTION AND CONTROL OF AFRICAN SWINE FEVER IN WILD BOAR AND DOMESTIC PIGS
"African swine fever (ASF) has recently transformed from an exotic disease to a panzootic threat to domestic and wild suids world-wide. Europe is currently facing different scenarios with front and point introductions, affected wild boar and domestic pig populations, epidemic and endemic situations. While our traditional prevention and control strategies work well with industrial pig farms, we quickly reach our limits when we have to control the disease in the abundant wild boar population or in regions with a majority of backyard farms. To turn the tide and to safeguard animal health, vaccines, especially oral vaccines for wild boar, could be the missing tool. There has been considerable progress in vaccine development and while we should continue to look for alternative approaches, we must now also dare to test the promising candidates beyond simple proof-of-concept studies. Only in this way can we generate the data base for benefit-risk analysis of whether and how current generation vaccines could be employed. Along these lines, this project sets out to test the vaccine candidate ""ASFV-G-ΔI177L"" in safety and efficacy tests after oral and intramuscular application as prescribed by international guidelines. This vaccine candidate has shown safety and very good protection under laboratory conditions and has been applied in the field in Vietnam. As a backup option, other promising candidates, “ASFV-G-ΔMGF” and “ASFV-G-Δ9GL/UK, will be tested in initial comparative trials. Accompanying the prescribed tests, our interdisciplinary consortium will characterize the protective immune responses, target the optimization of oral immunization and model tailored vaccination strategies. The data body generated in this project is crucial for benefit-risk-assessments at the level of all authorities entrusted with licensure and deployment of ASF vaccines and for this reason, relevant stakeholders will be involved from the start to guarantee full exploitation of our data."
Funded Companies:
| Company name | Funding amount |
| EIDGENOESSISCHES DEPARTEMENT DES INNERN | ? |
| Association Internationale de Standardisation Biologique Pour l'Europe(Iabs-EU) | €428,888 |
| DORSCH JULIAN | €149,941 |
| FRIEDRICH LOEFFLER INSTITUT - BUNDESFORSCHUNGSINSTITUT FUER TIERGESUNDHEIT | €1,560,749 |
| HELMHOLTZ-ZENTRUM FUR UMWELTFORSCHUNG GmbH - UFZ | €499,820 |
| Partikas Drosibas, Dzivnieku Veselibas UN Vides Zinatniskais Institutsbior | €302,013 |
| Sciensano | €1,270,546 |
| STICHTING WAGENINGEN RESEARCH | €1,304,363 |
| Universidad de Castilla - La Mancha | €789,875 |
Source: https://cordis.europa.eu/project/id/101136676
The filing refers to a past date, and does not necessarily reflect the current state. The current state is available on the following page: EIDGENOESSISCHES DEPARTEMENT DES INNERN, Berne, Switzerland.
The visualizations for "EIDGENOESSISCHES DEPARTEMENT DES INNERN - EU funding (€6,306,193): UNDERSTANDING PERFORMANCE CHARACTERISTICS OF LIVE ATTENUATED VACCINES FOR THE PREVENTION AND CONTROL OF AFRICAN SWINE FEVER IN WILD BOAR AND DOMESTIC PIGS"
are provided by
North Data
and may be reused under the terms of the
Creative Commons CC-BY license.
